Skip to content
Subscriber Only

Novartis to Add Warnings to Rasilez Blood-Pressure Drug

Novartis AG said it will add a warning to the label for its blood-pressure drug Rasilez in Europe to comply with a request from regulators.

Novartis is changing the product information for Rasilez, sold in the U.S. as Tekturna, to say that the drug should not be used to treat patients with diabetes or kidney problems who are taking certain other medicines, the Basel, Switzerland-based company said in a statement today.